Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2013 Oct;28(10):1333-9.
doi: 10.1007/s11606-013-2453-x. Epub 2013 Apr 26.

Identifying the risks of anticoagulation in patients with substance abuse

Lydia M Efird  1 , Donald R Miller, Arlene S Ash, Dan R Berlowitz, Al Ozonoff, Shibei Zhao, Joel I Reisman, Guneet K Jasuja, Adam J Rose
Affiliations
Multicenter Study

Identifying the risks of anticoagulation in patients with substance abuse

Lydia M Efird et al. J Gen Intern Med. 2013 Oct.

Abstract

Background: Warfarin is effective in preventing thromboembolic events, but concerns exist regarding its use in patients with substance abuse.

Objective: Identify which patients with substance abuse who receive warfarin are at risk for poor outcomes.

Design: Retrospective cohort study. Diagnostic codes, lab values, and other factors were examined to identify risk of adverse outcomes.

Patients: Veterans AffaiRs Study to Improve Anticoagulation (VARIA) database of 103,897 patients receiving warfarin across 100 sites.

Main measures: Outcomes included percent time in therapeutic range (TTR), a measure of anticoagulation control, and major hemorrhagic events by ICD-9 codes.

Results: Nonusers had a higher mean TTR (62 %) than those abusing alcohol (53 %), drugs (50 %), or both (44 %, p < 0.001). Among alcohol abusers, an increasing ratio of the serum hepatic transaminases aspartate aminotransferase/alanine aminotransferase (AST:ALT) correlated with inferior anticoagulation control; normal AST:ALT ≤ 1.5 predicted relatively modest decline in TTR (54 %, p < 0.001), while elevated ratios (AST:ALT 1.50-2.0 and > 2.0) predicted progressively poorer anticoagulation control (49 % and 44 %, p < 0.001 compared to nonusers). Age-adjusted hazard ratio for major hemorrhage was 1.93 in drug and 1.37 in alcohol abuse (p < 0.001 compared to nonusers), and remained significant after also controlling for anticoagulation control and other bleeding risk factors (1.69 p < 0.001 and 1.22 p = 0.003). Among alcohol abusers, elevated AST:ALT >2.0 corresponded to more than three times the hemorrhages (HR 3.02, p < 0.001 compared to nonusers), while a normal ratio AST:ALT ≤ 1.5 predicted a rate similar to nonusers (HR 1.19, p < 0.05).

Conclusions: Anticoagulation control is particularly poor in patients with substance abuse. Major hemorrhages are more common in both alcohol and drug users. Among alcohol abusers, the ratio of AST/ALT holds promise for identifying those at highest risk for adverse events.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Among patients receiving oral anticoagulation pharmacotherapy from the VA with alcohol abuse, patient-level percent time in therapeutic range (TTR) vs. AST:ALT ratio, plotted using a cubic smoothing spline.
See this image and copyright information in PMC

Comment in

References

    1. Compton WM, Thomas YF, Stinson FS, Grant BF. Prevalence, correlates, disability, and comorbidity of DSM-IV drug abuse and dependence in the United States: results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry. 2007;64:566–76. doi: 10.1001/archpsyc.64.5.566. - DOI - PubMed
    1. Hasin DS, Stinson FS, Ogburn E, Grant BF. Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry. 2007;64:830–42. doi: 10.1001/archpsyc.64.7.830. - DOI - PubMed
    1. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition) Chest. 2008;133:160S–98S. doi: 10.1378/chest.08-0670. - DOI - PubMed
    1. Havrda DE, Mai T, Chonlahan J. Enhanced antithrombotic effect of warfarin associated with low-dose alcohol consumption. Pharmacotherapy. 2005;25:303–7. doi: 10.1592/phco.25.2.303.56955. - DOI - PubMed
    1. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51. doi: 10.1056/NEJMoa0905561. - DOI - PubMed

Publication types

MeSH terms